Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 2/20 | 0.53 |
| ▸ | LCK | P06239 | 1/20 | 0.53 |
| ▸ | FGFR4 | P22455 | 8/20 | 0.51 |
| ▸ | ABL1 | P00519 | 4/20 | 0.47 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.47 |
| ▸ | KIT | P10721 | 1/20 | 0.47 |
| ▸ | SRC | P12931 | 1/20 | 0.47 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.47 |
| ▸ | JAK2 | O60674 | 2/20 | 0.43 |
| ▸ | JAK3 | P52333 | 2/20 | 0.43 |
| ▸ | TNK2 | Q07912 | 4/20 | 0.43 |
| ▸ | MAP4K2 | Q12851 | 4/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | WEE1 | P30291 | 1/20 | 0.41 |
| ▸ | BCR | P11274 | 1/20 | 0.40 |
| ▸ | BMX | P51813 | 1/20 | 0.40 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3970897 | 0.92 | MAPK14 (0.61) | MAPK14LCKFGFR4ABL1FGFR1 | |
| SCHEMBL4208611 | 0.87 | FGFR4 (0.53) | MAPK14LCKFGFR4ABL1FGFR1 | |
| SCHEMBL7847396 | 0.85 | ABL1 (0.39) | MAPK14LCKFGFR4ABL1FGFR1 | |
| SCHEMBL23653059 | 0.81 | FGFR4 (0.64) | MAPK14LCKFGFR4ABL1FGFR1 | |
| SCHEMBL3967358 | 0.80 | LCK (0.49) | MAPK14LCKFGFR4ABL1FGFR1 | |
| SCHEMBL3970398 | 0.80 | LCK (0.51) | MAPK14LCKFGFR4ABL1FGFR1 | |
| SCHEMBL6622549 | 0.79 | LCK (0.69) | MAPK14LCKFGFR4ABL1FGFR1 | |
| SCHEMBL6620252 | 0.78 | MAPK14 (0.66) | MAPK14LCKFGFR4ABL1FGFR1 | |
| SCHEMBL3977639 | 0.78 | FGFR4 (0.61) | MAPK14LCKFGFR4ABL1FGFR1 | |
| SCHEMBL3968867 | 0.78 | LCK (0.51) | MAPK14LCKFGFR4FGFR1PDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7501425-B1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyprimidines as inhibitors of cellular proliferation | WARNER LAMBERT COMPANY (US) | 2009-03-10 | — | — | US | claimed |
| EP-1801112-A1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation | Warner-Lambert Company LLC (US) | 2007-06-27 | — | — | EP | claimed |
| EP-1080092-A2 | BICYCLIC PYRIMIDINES AND BICYCLIC 3,4-DIHYDROPYRIMIDINES AS INHIBITORS OF CELLULAR PROLIFERATION | WARNER-LAMBERT COMPANY (US) | 2001-03-07 | — | — | EP | claimed |
| WO-1999061444-A2 | BICYCLIC PYRIMIDINES AND BICYCLIC 3,4-DIHYDROPYRIMIDINES AS INHIBITORS OF CELLULAR PROLIFERATION | WARNER-LAMBERT COMPANY (US) | 1999-12-02 | — | — | WO | claimed |
| US-7501425-B1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyprimidines as inhibitors of cellular proliferation | WARNER LAMBERT COMPANY (US) | 2009-03-10 | — | — | US | disclosed |
| EP-1801112-A1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation | Warner-Lambert Company LLC (US) | 2007-06-27 | — | — | EP | disclosed |
| US-20040044012-A1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation | DOBRUSIN ELLEN MYRA (US) | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044012-A1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation | CCNI, CCNH, CCNA1 | MAPK14 447/4885LCK 117/4885FGFR4 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.